FDA
-
-
-
-
-
-
-
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
-
-
-
-
-
-
-
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
-
-
-
-
-
-
-
Vallon Pharmaceuticals Inc. (VLON) Study for Lead Program, ADAIR, for the Treatment of ADHD Did Not Meet its Primary Endpoint
-
-
-
-
-
-
-
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
-
-
-
-
-
-
-
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
-
-
-
-
-
-
-
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
-
-
-
-
-
-
-
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
325,295 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

